107 related articles for article (PubMed ID: 12145998)
21. Prospective, double-blind, placebo-controlled, multicenter, randomized phase III study with orally administered budesonide for prevention of irinotecan (CPT-11)-induced diarrhea in patients with advanced colorectal cancer.
Karthaus M; Ballo H; Abenhardt W; Steinmetz T; Geer T; Schimke J; Braumann D; Behrens R; Behringer D; Kindler M; Messmann H; Boeck HP; Greinwald R; Kleeberg U
Oncology; 2005; 68(4-6):326-32. PubMed ID: 16020959
[TBL] [Abstract][Full Text] [Related]
22. [Chemotherapy-induced diarrhea].
Kobayashi K
Gan To Kagaku Ryoho; 2003 Jun; 30(6):765-71. PubMed ID: 12852342
[TBL] [Abstract][Full Text] [Related]
23. Alleviation of side effects induced by irinotecan hydrochloride (CPT-11) in rats by intravenous infusion.
Kurita A; Kado S; Kaneda N; Onoue M; Hashimoto S; Yokokura T
Cancer Chemother Pharmacol; 2003 Nov; 52(5):349-60. PubMed ID: 12904895
[TBL] [Abstract][Full Text] [Related]
24. Reducing irinotecan-associated diarrhea in children.
Wagner LM; Crews KR; Stewart CF; Rodriguez-Galindo C; McNall-Knapp RY; Albritton K; Pappo AS; Furman WL
Pediatr Blood Cancer; 2008 Feb; 50(2):201-7. PubMed ID: 17570704
[TBL] [Abstract][Full Text] [Related]
25. Thalidomide and irinotecan-associated diarrhea.
Tchekmedyian NS
Am J Clin Oncol; 2002 Jun; 25(3):324. PubMed ID: 12040298
[No Abstract] [Full Text] [Related]
26. Palifermin reduces diarrhea and increases survival following irinotecan treatment in tumor-bearing DA rats.
Gibson RJ; Bowen JM; Keefe DM
Int J Cancer; 2005 Sep; 116(3):464-70. PubMed ID: 15800945
[TBL] [Abstract][Full Text] [Related]
27. UFT/leucovorin plus irinotecan in advanced or metastatic colorectal cancer.
Price T; Hill M
Oncology (Williston Park); 2000 Oct; 14(10 Suppl 9):28-31. PubMed ID: 11098487
[TBL] [Abstract][Full Text] [Related]
28. Gastrointestinal toxicity or irinotecan.
Hecht JR
Oncology (Williston Park); 1998 Aug; 12(8 Suppl 6):72-8. PubMed ID: 9726096
[TBL] [Abstract][Full Text] [Related]
29. Phase I study of radical thoracic radiation, weekly irinotecan, and cisplatin in locally advanced non-small cell lung carcinoma.
Langer CJ; Somer R; Litwin S; Feigenberg S; Movsas B; Maiale C; Sherman E; Millenson M; Nicoloau N; Huang C; Treat J
J Thorac Oncol; 2007 Mar; 2(3):203-9. PubMed ID: 17410043
[TBL] [Abstract][Full Text] [Related]
30. Neomycin as secondary prophylaxis for irinotecan-induced diarrhea.
Schmittel A; Jahnke K; Thiel E; Keilholz U
Ann Oncol; 2004 Aug; 15(8):1296. PubMed ID: 15277273
[No Abstract] [Full Text] [Related]
31. Phase I/II study of weekly irinotecan and concurrent radiation therapy for locally advanced non-small cell lung cancer.
Takeda K; Negoro S; Kudoh S; Okishio K; Masuda N; Takada M; Tanaka M; Nakajima T; Tada T; Fukuoka M
Br J Cancer; 1999 Mar; 79(9-10):1462-7. PubMed ID: 10188891
[TBL] [Abstract][Full Text] [Related]
32. Weekly administration of irinotecan (CPT-11) plus cisplatin for non-small cell lung cancer.
Hino M; Kobayashi K; Yoshimura A; Takeda Y; Hisakatsu S; Yoneda S; Gemma A; Moriya H; Kudoh S;
Anticancer Res; 2006; 26(6C):4697-703. PubMed ID: 17214329
[TBL] [Abstract][Full Text] [Related]
33. A genome-wide association study for irinotecan-related severe toxicities in patients with advanced non-small-cell lung cancer.
Han JY; Shin ES; Lee YS; Ghang HY; Kim SY; Hwang JA; Kim JY; Lee JS
Pharmacogenomics J; 2013 Oct; 13(5):417-22. PubMed ID: 22664479
[TBL] [Abstract][Full Text] [Related]
34. Phase I/II study of escalating doses of nedaplatin in combination with irinotecan for advanced non-small-cell lung cancer.
Oshita F; Yamada K; Kato Y; Ikehara M; Noda K; Tanaka G; Nomura I; Suzuki R; Saito H
Cancer Chemother Pharmacol; 2003 Jul; 52(1):73-8. PubMed ID: 12750839
[TBL] [Abstract][Full Text] [Related]
35. Phase I study and pharmacokinetics of CPT-11 with 5-day continuous infusion.
Ohe Y; Sasaki Y; Shinkai T; Eguchi K; Tamura T; Kojima A; Kunikane H; Okamoto H; Karato A; Ohmatsu H
J Natl Cancer Inst; 1992 Jun; 84(12):972-4. PubMed ID: 1321253
[No Abstract] [Full Text] [Related]
36. [Clinical evaluation of irinotecan combined with cisplatin by divided administration in patients with untreated primary non-small cell lung cancer].
Asano T; Namikawa O; Yamamoto A; Sano T; Mukai J; Kawaji K; Kobayashi M
Nihon Kokyuki Gakkai Zasshi; 1998 Sep; 36(9):771-5. PubMed ID: 9866979
[TBL] [Abstract][Full Text] [Related]
37. Irinotecan and carboplatin in metastatic or recurrent NSCLC: an update.
Read W; McLeod H; Govindan R
Oncology (Williston Park); 2004 Dec; 18(14 Suppl 14):15-7. PubMed ID: 15685828
[TBL] [Abstract][Full Text] [Related]
38. [Irinotecan plus cisplatin for the treatment of advanced non-small cell lung cancer].
Zhang XR; Zhu YZ; Xiu QY; Han FC; Liu DQ; Chu DT
Zhonghua Zhong Liu Za Zhi; 2006 Oct; 28(10):777-9. PubMed ID: 17366795
[TBL] [Abstract][Full Text] [Related]
39. Prevention of irinotecan induced diarrhea by probiotics: A randomized double blind, placebo controlled pilot study.
Mego M; Chovanec J; Vochyanova-Andrezalova I; Konkolovsky P; Mikulova M; Reckova M; Miskovska V; Bystricky B; Beniak J; Medvecova L; Lagin A; Svetlovska D; Spanik S; Zajac V; Mardiak J; Drgona L
Complement Ther Med; 2015 Jun; 23(3):356-62. PubMed ID: 26051570
[TBL] [Abstract][Full Text] [Related]
40. Dose escalation study of paclitaxel in combination with fixed-dose irinotecan in patients with advanced non-small cell lung cancer (JCOG 9807).
Yamada K; Ikehara M; Tanaka G; Nomura I; Oshita F; Noda K
Oncology; 2004; 66(2):94-100. PubMed ID: 15138360
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
